160 related articles for article (PubMed ID: 29181687)
21. Amentoflavone Enhances the Therapeutic Efficacy of Sorafenib by Inhibiting Anti-apoptotic Potential and Potentiating Apoptosis in Hepatocellular Carcinoma
Tsai JJ; Hsu FT; Pan PJ; Chen CW; Kuo YC
Anticancer Res; 2018 Apr; 38(4):2119-2125. PubMed ID: 29599330
[TBL] [Abstract][Full Text] [Related]
22. An Explorative Analysis for the Role of Serum miR-10b-3p Levels in Predicting Response to Sorafenib in Patients with Advanced Hepatocellular Carcinoma.
Yoon EL; Yeon JE; Ko E; Lee HJ; Je JH; Yoo YJ; Kang SH; Suh SJ; Kim JH; Seo YS; Yim HJ; Byun KS
J Korean Med Sci; 2017 Feb; 32(2):212-220. PubMed ID: 28049231
[TBL] [Abstract][Full Text] [Related]
23. Sorafenib Inhibition of Mcl-1 Accelerates ATRA-Induced Apoptosis in Differentiation-Responsive AML Cells.
Wang R; Xia L; Gabrilove J; Waxman S; Jing Y
Clin Cancer Res; 2016 Mar; 22(5):1211-21. PubMed ID: 26459180
[TBL] [Abstract][Full Text] [Related]
24. Targeted delivery of miR-200c/DOC to inhibit cancer stem cells and cancer cells by the gelatinases-stimuli nanoparticles.
Liu Q; Li RT; Qian HQ; Wei J; Xie L; Shen J; Yang M; Qian XP; Yu LX; Jiang XQ; Liu BR
Biomaterials; 2013 Sep; 34(29):7191-203. PubMed ID: 23806972
[TBL] [Abstract][Full Text] [Related]
25. DCT015, a new sorafenib derivate, inhibits tumor growth and angiogenesis in gastric cancer models.
Wang W; Wang H; Ni Y; Yao Z; Ye L; Tian J
Tumour Biol; 2016 Jul; 37(7):9221-32. PubMed ID: 26768619
[TBL] [Abstract][Full Text] [Related]
26. Programmed death-ligand 1 monoclonal antibody-linked immunoliposomes for synergistic efficacy of miR-130a and oxaliplatin in gastric cancers.
Wang F; Sun Y; Shi J
Nanomedicine (Lond); 2019 Jul; 14(13):1729-1744. PubMed ID: 31290727
[No Abstract] [Full Text] [Related]
27. Inhibition of the AKT/mTOR Pathway Augments the Anticancer Effects of Sorafenib in Thyroid Cancer.
Yi H; Ye X; Long B; Ye T; Zhang L; Yan F; Yang Y; Li L
Cancer Biother Radiopharm; 2017 Jun; 32(5):176-183. PubMed ID: 28622037
[TBL] [Abstract][Full Text] [Related]
28. Co-delivery of sorafenib and siVEGF based on mesoporous silica nanoparticles for ASGPR mediated targeted HCC therapy.
Zheng G; Zhao R; Xu A; Shen Z; Chen X; Shao J
Eur J Pharm Sci; 2018 Jan; 111():492-502. PubMed ID: 29107835
[TBL] [Abstract][Full Text] [Related]
29. Nanostructured lipid carriers loaded with tributyrin as an alternative to improve anticancer activity of all-trans retinoic acid.
Silva EL; Carneiro G; Caetano PA; Goulart G; Ferreira Costa D; de Souza-Fagundes EM; Gomes DA; Ferreira LA
Expert Rev Anticancer Ther; 2015 Feb; 15(2):247-56. PubMed ID: 25611812
[TBL] [Abstract][Full Text] [Related]
30. Active Targeting of Sorafenib: Preparation, Characterization, and In Vitro Testing of Drug-Loaded Magnetic Solid Lipid Nanoparticles.
Grillone A; Riva ER; Mondini A; Forte C; Calucci L; Innocenti C; de Julian Fernandez C; Cappello V; Gemmi M; Moscato S; Ronca F; Sacco R; Mattoli V; Ciofani G
Adv Healthc Mater; 2015 Aug; 4(11):1681-90. PubMed ID: 26039933
[TBL] [Abstract][Full Text] [Related]
31. In vitro and in vivo evaluation of drug-eluting microspheres designed for transarterial chemoembolization therapy.
Wang Y; Molin DG; Sevrin C; Grandfils C; van den Akker NM; Gagliardi M; Knetsch ML; Delhaas T; Koole LH
Int J Pharm; 2016 Apr; 503(1-2):150-62. PubMed ID: 26965198
[TBL] [Abstract][Full Text] [Related]
32. The synergistic antitumor effects of all-trans retinoic acid and C-phycocyanin on the lung cancer A549 cells in vitro and in vivo.
Li B; Gao MH; Chu XM; Teng L; Lv CY; Yang P; Yin QF
Eur J Pharmacol; 2015 Feb; 749():107-14. PubMed ID: 25617793
[TBL] [Abstract][Full Text] [Related]
33. Nanomedicine-based combination of gambogic acid and retinoic acid chlorochalcone for enhanced anticancer efficacy in osteosarcoma.
Liu L; Qi XJ; Zhong ZK; Zhang EN
Biomed Pharmacother; 2016 Oct; 83():79-84. PubMed ID: 27470553
[TBL] [Abstract][Full Text] [Related]
34. All-trans retinoic acid arrests neuroblastoma cells in a dormant state. Subsequent nerve growth factor/brain-derived neurotrophic factor treatment adds modest benefit.
Cernaianu G; Brandmaier P; Scholz G; Ackermann OP; Alt R; Rothe K; Cross M; Witzigmann H; Tröbs RB
J Pediatr Surg; 2008 Jul; 43(7):1284-94. PubMed ID: 18639684
[TBL] [Abstract][Full Text] [Related]
35. A network including PU.1, Vav1 and miR-142-3p sustains ATRA-induced differentiation of acute promyelocytic leukemia cells - a short report.
Grassilli S; Nika E; Lambertini E; Brugnoli F; Piva R; Capitani S; Bertagnolo V
Cell Oncol (Dordr); 2016 Oct; 39(5):483-489. PubMed ID: 27480083
[TBL] [Abstract][Full Text] [Related]
36. Nanoparticle delivery and combination therapy of gambogic acid and all-trans retinoic acid.
Yao J; Li Y; Sun X; Dahmani FZ; Liu H; Zhou J
Int J Nanomedicine; 2014; 9():3313-24. PubMed ID: 25045262
[TBL] [Abstract][Full Text] [Related]
37. Polymer-lipid hybrid nanoparticles-based paclitaxel and etoposide combinations for the synergistic anticancer efficacy in osteosarcoma.
Duan R; Li C; Wang F; Yangi JC
Colloids Surf B Biointerfaces; 2017 Nov; 159():880-887. PubMed ID: 28892872
[TBL] [Abstract][Full Text] [Related]
38. Efficiency of All-Trans Retinoic Acid on Gastric Cancer: A Narrative Literature Review.
Bouriez D; Giraud J; Gronnier C; Varon C
Int J Mol Sci; 2018 Oct; 19(11):. PubMed ID: 30380687
[TBL] [Abstract][Full Text] [Related]
39. Combination of paclitaxel- and retinoic acid-incorporated nanoparticles for the treatment of CT-26 colon carcinoma.
Hong GY; Jeong YI; Lee SJ; Lee E; Oh JS; Lee HC
Arch Pharm Res; 2011 Mar; 34(3):407-17. PubMed ID: 21547672
[TBL] [Abstract][Full Text] [Related]
40. Liposomes assembled from dimeric retinoic acid phospholipid with improved pharmacokinetic properties.
Lu L; Du Y; Ismail M; Ling L; Yao C; Fu Z; Li X
Eur J Pharm Sci; 2018 Jan; 112():186-194. PubMed ID: 29162478
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
